## 2'-Deoxycytidine-<sup>13</sup>C<sub>9</sub>

Cat. No.:	HY-D0184S5	NH <sub>2</sub>
Molecular Formula:	<sup>13</sup> C <sub>9</sub> H <sub>13</sub> N <sub>3</sub> O <sub>4</sub>	H <sup>13</sup> C N
Molecular Weight:	236.15	II T
Target:	Isotope-Labeled Compounds; Endogenous Metabolite	H <sup>13</sup> C N C
Pathway:	Others; Metabolic Enzyme/Protease	<sup>11</sup> <sup>3</sup> CH <sub>2</sub> ∫
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	H <sup>13</sup> C H <sup>13</sup> C H <sup>13</sup> C H <sup>13</sup> C H

BIOLOGICAL ACTI	
Description	2'-Deoxycytidine <sup>-13</sup> C <sub>9</sub> (Deoxycytidine <sup>-13</sup> C <sub>9</sub> ; Cytosine deoxyriboside <sup>-13</sup> C <sub>9</sub> ; Deoxyribose cytidine <sup>-13</sup> C <sub>9</sub> ) is <sup>13</sup> C-labeled 2'- Deoxycytidine (HY-D0184). 2'-Deoxycytidine, a deoxyribonucleoside, could inhibit biological effects of Bromodeoxyuridine (Brdu).
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

[2]. Horn D, et al. Inhibition of biological effects of bromodeoxyuridine by deoxycytidine: correlation with decreased incorporation of bromodeoxyuridine into DNA. Somatic Cell Genet. 1976 Sep;2(5):469-81.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1



Ò

**Product** Data Sheet